Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulouse – page 126

1 521 clinical trials in Toulouse, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulouse at a glance
1 521
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 521 trials in Toulouse

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Acute myeloid leukaemia+1

Not recruiting

Study of ASTX727 and Donor Lymphocyte Infusions for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia After Stem Cell Transplant

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Systemic lupus erythematosus

Not recruiting

Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Kaposi's sarcoma

Not recruiting

Study of Pembrolizumab for Patients with Classic or Endemic Kaposi's Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Cervix carcinoma

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Acute kidney injury

Not recruiting

Study on the Effects of Irbesartan After Acute Kidney Injury in Patients Discharged from ICU

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer+5

Not recruiting

Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroestradiol F-18
  • Sponsor:GE Healthcare Limited

Acute myeloid leukaemia

Not recruiting

Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

  • TTR Amyloidosis Cardiomyopathy
  • Heart Failure Prevention
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

  • Head & Neck Squamous Cell Carcinoma
  • Gastric and GEJ Cancer
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

  • Frontotemporal Dementia
  • Essential Tremor
  • Traumatic Brain Injury
  • Multiple Sclerosis
04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

  • Crohn's Disease
  • Psoriatic Arthritis
  • Myasthenia Gravis
  • Idiopathic Pulmonary Fibrosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.